Latest News

7 July 2020

Journal of Parkinson's Disease Achieves Significant Impact Factor Increase

JPD 2019 Impact Factor 5.178

Amsterdam, NL – The Journal of Parkinson's Disease (JPD) and its publisher IOS Press are proud to announce that JPD's Journal Impact Factor has increased to 5.178 according to Clarivate's 2020 edition of the Web of Science Journal Citation Reports (JCR). This represents an impressive 40% increase from last year.

4 June 2020

Growth Factors and Parkinson's Disease – Where Next?

Growth factors such as glial cell line-derived neurotrophic factor (GDNF) were initially thought to be exciting new treatments for Parkinson’s disease, but trials have been disappointing. A panel of prominent leaders in the field convened to discuss whether there is a future for this approach and what any future PD trial involving GDNF and other GDNF family neurotrophic factors should consider. Their discussions and recommendations are published in the Journal of Parkinson's Disease.

6 May 2020

New Trial Platform Could Accelerate Finding a Cure for Parkinson's Disease

Despite 30 years of research, not a single therapy has been found to successfully delay or stop the progression of Parkinson's disease. In the Journal of Parkinson's Disease scientists report on the possibility of using a multi-arm, multi-stage trial platform to evaluate several potential therapies at once, using lessons learned from other diseases.

5 May 2020

New Evidence that Higher Caffeine and Urate Levels Are Protective Against Parkinson’s Disease

Two purines, caffeine and urate, have been associated with a reduced risk of Parkinson's disease (PD) in multiple study groups and populations. Analysis of data from the Harvard Biomarkers Study shows that lower levels of caffeine consumption and lower blood urate are inversely associated with PD, strengthening the links between caffeine intake and urate levels and PD, reports a study in JPD.


Subscribe to Latest News